Lung tumor-associated antigen (LTAA)

Lung tumor-associated antigens (LTAAs) represent a heterogeneous group of molecules, including proteins, glycoproteins, and glycolipids, that are either uniquely expressed or significantly overexpressed on the surface of lung cancer cells compared to normal lung tissue (Source: PubMed, PMID: 25650605). These antigens serve as critical targets for the development of immunotherapies, particularly cancer vaccines and adoptive cell therapies, aimed at stimulating the patient's immune system to recognize and destroy malignant cells (Source: NIH, National Cancer Institute). Common examples of LTAAs include MUC1, Carcinoembryonic Antigen (CEA), NY-ESO-1, and MAGE-A3, which are often targeted collectively in polyvalent vaccine formulations like Belagenpumatucel-L to address the high degree of intratumoral heterogeneity in non-small cell lung cancer (Source: Journal of Thoracic Oncology, DOI: 10.1097/JTO.0b013e318219999a). By targeting multiple antigens simultaneously, these therapies attempt to minimize the risk of antigenic escape, a process where tumor cells lose expression of a single target to evade immune detection (Source: Nature Reviews Cancer, DOI: 10.1038/nrc.2016.107). Despite their potential, the use of LTAAs as therapeutic targets faces challenges such as the low immunogenicity of self-antigens and the immunosuppressive microenvironment of the lung tumor (Source: Frontiers in Immunology, DOI: 10.3389/fimmu.2020.01436).

Other names

Tumor-associated antigens (TAAs)Lung cancer antigensLTAAsLung tumor antigens

Active immunotherapy and vaccine-mediated immune stimulation through the presentation of multiple tumor-specific antigens to the host immune system.